Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Entero Therapeutics, Inc. (NasdaqCM: ENTO) and Journey Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the proposed transaction, Journey shareholders will acquire 99% of the equity of Entero. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Entero shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([e-mail]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-ento/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114075419/en/

The Entero Therapeutics Stock at the time of publication of the news with a fall of -17,24 % to 0,521USD on NYSE stock exchange (14. November 2024, 23:20 Uhr).